BPH ENERGY LIMITED 
By
18 January 2013
ASX Market Announcements
Australian Securities Exchange Limited
10th Floor, 20 Bond Street
SYDNEY NSW 2000
Please find attached an operational update from BPH Energy Ltd (ASX: BPH) investee company Diagnostic
Array Systems Pty Ltd.
Yours sincerely,
Deborah Ambrosini
Director and Company Secretary
BPH Energy Limited ACN 95 912 002PO Box 317, North Perth, Western Australia 6906
14 View Street, North Perth, Western Australia 6006 admin@bphenergy.com.au www.bphenergy.com.au
T: +61 8 9328 8366 F: +61 8 9328 8733
18 January 2013
ASX Market Announcements
Australian Securities Exchange Limited
10th Floor, 20 Bond Street
SYNDEY NSW 2000
Diagnostic Array Systems Pty Ltd ("DAS") is pleased to announce it has been granted a Japanese patent relating to its BacTracTM System, a diagnostic tool for the identification of multiple respiratory pathogens. The patent entitled 'Method for the Detection and/or identification of a microorganism' is valid until July 2026. The patent describes a method for the simultaneous detection or identification of multiple microorganisms from a single patient sample.
DAS Chairman, Mr David Breeze stated 'We are very pleased to secure DAS' first granted patent relating to the BactracTM System. The granting of this patent paves the way for the Company's other pending patent applications. The detection of multiple respiratory pathogens from a single sputum sample is of significant commercial value and the granting of this patent greatly improves DAS' IP offering'.
DAS holds intellectual property for the BactracTM System in Australia, Canada, Japan and the United States.
The BactracTM System is a diagnostic test for the detection of respiratory infections (e.g. diagnosis of Pneumonia, Tuberculosis (TB) and Legionella disease). The BactracTM System identifies the cause of disease by testing for multiple bacteria in a single sputum sample. The test has important implications for the clinical management of infectious diseases by identifying the specific bacteria responsible for a disease and suggesting the most effective therapy. Utilisation of the novel test is intended to provide more information, more quickly than alternative methods. It has the potential to accelerate therapeutic treatment, lead to a reduction in hospitalisations and help reduce the overuse of antibiotics.
Yours Sincerely,
David Breeze
Director
ACN 103 314 049
PO box 317, North Perth, WA, 6906
14 View Street, North Perth, Western Australia
T: + 61 8 9328 8366 F: +61 8 9328 8733 admin@bphenergy.com.au www.bphenergy.com.au
|
distributed by
|
